Darrell Triulzi

Sickle Cell Disease and Cardiovascular Risk- Red Cell Exchange SCD-CARRE

National Heart, Lung, and Blood Institute · UH3

PI · $6.3M · University of Maryland Baltimore

Pragmatic, Prehospital Group O Whole Blood Early Resuscitation Pilot Trial

National Heart, Lung, and Blood Institute · R34

PI · $593.8K · University of Pittsburgh at Pittsburgh

1/2 Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE Trial)

National Heart, Lung, and Blood Institute · UG3

PI · $1.5M · University of Pittsburgh at Pittsburgh

Recipient Epidemiology and Donor Evaluation Study III (REDS-III) - Domestic Site - Phase 3

National Heart, Lung, and Blood Institute · N01

Contact PI · $3.7M · Yale University

Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

Principal investigator · Active not recruiting · Phase 3

University of Pittsburgh

Transfusion of Biotin-Labeled Red Blood Cells

Principal investigator · Terminated · Phase 2

Gladwin, Mark, MD

Red Cell Storage Duration Study

Principal investigator · Completed · Phase 3

Carelon Research

Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)

Principal investigator · Terminated · Phase 3

Carelon Research